SARS-CoV-2 and the Possible Role of Raf/MEK/ERK Pathway in Viral Survival: Is This a Potential Therapeutic Strategy for COVID-19?

Ghasemnejad-Berenji, Morteza; Pashapour, Sarvin

Ghasemnejad-Berenji, Morteza; Pashapour, Sarvin.

Ghasemnejad-Berenji M; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran, morteza.ghasemnejad@yahoo.com.
Pashapour S; Department of Pediatrics, Faculty of Medicine, Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran.

Pharmacology ; 106(1-2): 119-122, 2021.

Article in English | MEDLINE | ID: covidwho-1066970

Subject(s)

COVID-19/metabolism; MAP Kinase Signaling System/physiology; SARS-CoV-2/metabolism; raf Kinases/metabolism; Animals; Antiviral Agents/administration & dosage; Cell Survival/drug effects; Cell Survival/physiology; Enzyme Inhibitors/administration & dosage; Humans; MAP Kinase Signaling System/drug effects; SARS-CoV-2/drug effects; raf Kinases/antagonists & inhibitors; COVID-19 Drug Treatment

Keywords

COVID-19; RNA viruses; Raf/MEK/ERK signaling; Viral life cycle; Viral survival

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: MAP Kinase Signaling System / Raf Kinases / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: Pharmacology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google